Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.
Eur J Cancer
; 156: 125-126, 2021 10.
Article
in English
| MEDLINE | ID: covidwho-1397326
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunogenicity, Vaccine
/
COVID-19 Vaccines
/
COVID-19
/
Neoplasms
Type of study:
Cohort study
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Eur J Cancer
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS